Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP Chief Legal Officer | February 13, 2026 | February 18, 2026 |
| INVACARE HOLDINGS CorpIVC · Entity 86444 | Director | April 01, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 8,450 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 8,450 · Balance 8,450 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
INVACARE HOLDINGS Corp
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 104,499 |
Reported balance
After 2022-04-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-04-01 · Grant · Acquired 39,474 · Balance 104,499 F1: Restricted stock units granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2023. F2: Includes 13,388 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan, all of which vest in full on May 15, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2023.
F2: Includes 13,388 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan, all of which vest in full on May 15, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2020 Filed Feb 14, 2020 23:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 756 | $331.76 | $250,810.56 |
DisclosureSEC source: 0001127602-20-005772 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,955 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005772 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 17:04 UTC | INVACARE HOLDINGS Corp IVC · Entity 86444 | GrantCommon Shares | 18,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020307 · doc4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,198 F1 · shares: Restricted stock units granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2020. F2 · balance_after: Includes 6,708 previously reported restricted stock units issued pursuant to the Invacare Corporation 2013 Equity Compensation Plan, all of which vest in full on May 15, 2019. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,395 | Not disclosed Strike: $49.65 | Not disclosed |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · derivative · entry 7 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,395 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F1 · kind: The stock option was automatically exercised on a net share settlement basis immediately before its expiration, in accordance with its terms. The Company delivered to the reporting person the number of shares underlying the stock option less the number of shares having a Fair Market Value on the date of such exercise equal to (i) the aggregate exercise price for the stock option and (ii) the amount necessary to satisfy any federal, state and local withholding taxes related to such exercise. F2 · shares: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5 · derivative.exercise_date: The stock options become exercisable in four (4) equal annual installments commencing one year after the grant date of 02/24/09. F2 · derivative.underlying_shares: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 819 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · derivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 819 shares Expires 2019-02-22 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,663 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · derivative · entry 5 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819 Underlying: Common Stock · 1,663 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 739 | $325.33 | $240,418.87 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,976 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 3,370 | $325.33 | $1,096,362.10 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,715 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 6,395 | $48.52 | $310,285.40 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option was automatically exercised on a net share settlement basis immediately before its expiration, in accordance with its terms. The Company delivered to the reporting person the number of shares underlying the stock option less the number of shares having a Fair Market Value on the date of such exercise equal to (i) the aggregate exercise price for the stock option and (ii) the amount necessary to satisfy any federal, state and local withholding taxes related to such exercise. F2 · shares: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:53 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,033 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007250 · form4.xml · derivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,724 Underlying: Common Stock · 1,033 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:53 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,685 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007250 · form4.xml · derivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,757 Underlying: Common Stock · 1,685 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:53 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 749 | $332.87 | $249,319.63 |
DisclosureSEC source: 0001127602-19-007250 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,027 Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:53 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007250 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,020 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006073 · form4.xml · derivative · entry 8 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,020 Underlying: Common Stock · 10,020 shares Expires 2022-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006073 · form4.xml · derivative · entry 7 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,742 Underlying: Common Stock · 1,448 shares Expires 2021-02-12 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,920 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006073 · form4.xml · derivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,190 Underlying: Common Stock · 1,920 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,348 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006073 · form4.xml · derivative · entry 5 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,697 Underlying: Common Stock · 1,348 shares Expires 2020-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 619 | $319.43 | $197,727.17 |
DisclosureSEC source: 0001127602-19-006073 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,091 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006073 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 402 | $319.43 | $128,410.86 |
DisclosureSEC source: 0001127602-19-006073 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,790 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:04 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006073 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 17:39 UTC | INVACARE HOLDINGS Corp IVC · Entity 86444 | GrantCommon Shares | 6,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020945 · doc4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,153 F1 · shares: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2019. F2 · balance_after: Includes 8,606 previously reported restricted stock units issued pursuant to the Invacare Corporation 2013 Equity Compensation Plan that vest in full on May 15, 2018. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:22 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,091 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008811 · form4.xml · derivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,091 shares Expires 2018-02-23 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 857 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008811 · form4.xml · derivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,091 Underlying: Common Stock · 857 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 381 | $292.78 | $111,549.18 |
DisclosureSEC source: 0001127602-18-008811 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,844 Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 857 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008811 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:10 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 843 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008398 · form4.xml · derivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,482 Underlying: Common Stock · 843 shares Expires 2019-02-22 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,635 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008398 · form4.xml · derivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,325 Underlying: Common Stock · 1,635 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 727 | $284.81 | $207,056.87 |
DisclosureSEC source: 0001127602-18-008398 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,368 Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008398 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,006 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007183 · form4.xml · derivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,442 Underlying: Common Stock · 1,006 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,712 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007183 · form4.xml · derivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,448 Underlying: Common Stock · 1,712 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 510 | $299.38 | $152,683.80 |
DisclosureSEC source: 0001127602-18-007183 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,460 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007183 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:44 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,110 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006188 · form4.xml · derivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,110 Underlying: Common Stock · 10,110 shares Expires 2021-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:44 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 4,045 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006188 · form4.xml · derivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,045 Underlying: Common Stock · 4,045 shares Expires 2020-02-12 F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 20:22 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 4,974 | $290.01 | $1,442,509.74 |
DisclosureSEC source: 0001127602-17-024164 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,258 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| July 19, 2017 Filed Jul 20, 2017 21:00 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 7,758 | $285.00 | $2,211,030.00 |
DisclosureSEC source: 0001127602-17-023953 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Corp Svc & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,232 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 16:43 UTC | INVACARE HOLDINGS Corp IVC · Entity 86444 | GrantCommon Shares | 8,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-021750 · doc4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,445 F1 · shares: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2018. F2 · balance_after: Includes 2,839 previously reported restricted stock units issued pursuant to the Invacare Corporation 2013 Equity Compensation Plan that vest in full on February 20, 2018. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · derivative · entry 16 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires 2017-02-12 F11 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,197 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · derivative · entry 15 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 2,197 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F10 · shares: This award was previously reported as covering 2,147 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F11 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). F10 · derivative.underlying_shares: This award was previously reported as covering 2,147 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F10 · balance_after: This award was previously reported as covering 2,147 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · derivative · entry 14 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,259 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F9 · shares: This award was previously reported as covering 2,674 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F9 · derivative.underlying_shares: This award was previously reported as covering 2,674 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F9 · balance_after: This award was previously reported as covering 2,674 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · derivative · entry 13 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,960 Underlying: Common Stock · 1,375 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F8 · shares: This award was previously reported as covering 7,270 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F8 · derivative.underlying_shares: This award was previously reported as covering 7,270 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F8 · balance_after: This award was previously reported as covering 7,270 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 728 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · derivative · entry 12 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948 Underlying: Common Stock · 728 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7 · shares: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F7 · derivative.underlying_shares: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F7 · balance_after: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,216 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · derivative · entry 11 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676 Underlying: Common Stock · 1,216 shares Expires 2018-02-23 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,103 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · derivative · entry 10 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,335 Underlying: Common Stock · 1,103 shares Expires 2019-02-22 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,477 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · derivative · entry 9 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,259 Underlying: Common Stock · 1,477 shares Expires 2017-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,034 | $274.76 | $284,101.84 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · nonDerivative · entry 8 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,990 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · nonDerivative · entry 7 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.